EHA: Johnson & Johnson, bolsters Darzalex’s myeloma lead with ‘unprecedented’ survival data

Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. Adding Darzalex to Bristol Myers Squibb’s Revlimid and […]